Picture of Arecor Therapeutics logo

AREC Arecor Therapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

REG - Arecor Therapeutics - Holding(s) in Company

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220804:nRSD9814Ua&default-theme=true

RNS Number : 9814U  Arecor Therapeutics PLC  04 August 2022

TR-1: Standard form for notification of major holdings

 

 NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the
 FCA in Microsoft Word format if possible)(i)

 1a. Identity of the issuer or the underlying issuer of existing shares to                                                                                    Arecor Therapeutics plc
 which voting rights are attached(ii):
 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an
 "X" if appropriate)
 Non-UK issuer
 2. Reason for the notification (please mark the appropriate box or boxes with
 an "X")
 An acquisition or disposal of voting rights
 An acquisition or disposal of financial instruments
 An event changing the breakdown of voting rights                                                                                                                                                                                                          X
 Other (please specify)(iii):
 3. Details of person subject to the notification obligation(iv)
 Name                                                                                                                                                         Unicorn Asset Management Limited
 City and country of registered office (if applicable)                                                                                                        London, United Kingdom
 4. Full name of shareholder(s) (if different from 3.)(v)
 Name                                                                                                                                                         Unicorn AIM VCT plc
 City and country of registered office (if applicable)                                                                                                        Newton Abbot, United Kingdom
 5. Date on which the threshold was crossed or reached(vi):                                                                                                   04 August 2022
 6. Date on which issuer notified (DD/MM/YYYY):                                                                                                               04 August 2022
 7. Total positions of person(s) subject to the notification obligation
                                                                            % of voting rights attached to shares (total of 8. A)  % of voting rights through financial instruments      Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer (8.A + 8.B) (vii)

(total of 8.B 1 + 8.B 2)
 Resulting situation on the date on which threshold was crossed or reached  3.93%                                                                                                        3.93%                           1,198,828
 Position of previous notification (if                                      4.18%                                                                                                        4.18%

 applicable)

 

 8. Notified details of the resulting situation on the date on which the
 threshold was crossed or reached(viii)
 A: Voting rights attached to shares
 Class/type of                                  Number of voting rights(ix)                                                                                 % of voting rights

shares

 ISIN code (if possible)
                                                Direct                                          Indirect                                                    Direct                                           Indirect

                                                (Art 9 of Directive 2004/109/EC) (DTR5.1)       (Art 10 of Directive 2004/109/EC) (DTR5.2.1)                (Art 9 of Directive 2004/109/EC) (DTR5.1)        (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
 Ordinary shares GB00BMWLM973                                                                            1,198,828                                                                                           3.93%

 SUBTOTAL 8. A                                  1,198,828                                                                                                   3.93%

 B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
 (DTR5.3.1.1 (a))
 Type of financial instrument                   Expiration              Exercise/                                                   Number of voting rights that may be acquired if the instrument is        % of voting rights

date(x)
Conversion Period(xi)

                                                                                                                                    exercised/converted.

                                                                        SUBTOTAL 8. B 1

 B 2: Financial Instruments with similar economic effect according to Art.
 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
 Type of financial instrument  Expiration                               Exercise/                                 Physical or cash                                                  Number of voting rights  % of voting rights

date(x)
Conversion Period (xi)

                                                                                                                  settlement(xii)

                                                                                                                  SUBTOTAL 8.B.2

 

 9. Information in relation to the person subject to the notification
 obligation (please mark the

 applicable box with an "X")
 Person subject to the notification obligation is not controlled by any natural                                                                                                                                           X
 person or legal entity and does not control any other undertaking(s) holding
 directly or indirectly an interest in the (underlying) issuer(xiii)
 Full chain of controlled undertakings through which the voting rights and/or
 the

financial instruments are effectively held starting with the ultimate
 controlling natural person or legal entity(xiv) (please add additional rows as
 necessary)
 Name(xv)                    % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                         than the notifiable threshold

 10. In case of proxy voting, please identify:
 Name of the proxy holder                                                                                See Section 4
 The number and % of voting rights held
 The date until which the voting rights will be held

 11. Additional information(xvi)
 Figures are based on total voting rights of 30,486,750

 

 Place of completion  Unicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse
                      Square, London, EC1M 6AU
 Date of completion   04 August 2022

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUSRORUWUWRAR

Recent news on Arecor Therapeutics

See all news